Tobias K. Gustavsson

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer.

Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer.

Journal: Gut

Published: November 15, 2025

Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain Barrier.

Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain Barrier.

Journal: Molecular pharmaceutics

Published: November 06, 2025

Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.

Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate.

Journal: Cell death & disease

Published: May 14, 2025

Head-to-Head Comparison of the in Vivo Performance of Highly Reactive and Polar 18F-Labeled Tetrazines.

Head-to-Head Comparison of the in Vivo Performance of Highly Reactive and Polar 18F-Labeled Tetrazines.

Journal: Molecular pharmaceutics

Published: March 13, 2025

An 211At-labeled Tetrazine for Pretargeted Therapy.

An 211At-labeled Tetrazine for Pretargeted Therapy.

Journal: Journal of medicinal chemistry

Published: February 18, 2025

Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.

Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.

Journal: NPJ precision oncology

Published: January 17, 2025

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.

Journal: Blood

Published: December 20, 2024

The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.

The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.

Journal: Blood

Published: December 20, 2024

Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells.

Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells.

Journal: STAR protocols

Published: October 11, 2024

Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles.

Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles.

Journal: Journal of extracellular vesicles

Published: September 06, 2024

Use of the Malaria Protein VAR2CSA for the Detection of Small Extracellular Vesicles to Diagnose Adenocarcinoma.

Use of the Malaria Protein VAR2CSA for the Detection of Small Extracellular Vesicles to Diagnose Adenocarcinoma.

Journal: Journal of extracellular vesicles

Published: July 29, 2024

Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.

Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.

Journal: EMBO molecular medicine

Published: May 31, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026